Evidence map›Paper›PMID 37848562›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2024

Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.

Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Tomohiko Kanaoka, Hiromichi Wakui, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Shun Ito and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Salt and chronic kidney disease.Nature reviews. Nephrology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 1 country.

Shunichiro TsukamotoDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuo KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. k-taishi@xc4.so-net.ne.jp.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of internal medicine, Tokai University School of Medicine, lsehara, Japan.
Nobuo HatoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Tomohiko KanaokaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiromichi WakuiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiroyuki SakaiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Takayuki FurukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Keiichi ChinCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Shun ItoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Daisuke SuzukiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Tomoya UmezonoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Togo AoyamaDivision of Nephrology, Department of internal medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Shinichi NakajimaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Toshimasa HishikiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Yutaka HatoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Masahiro HayashiCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Hidetoshi ShimuraCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Fuyuki MinagawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Atsuko MokuboCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Masahiro TakihataCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Kazuyoshi SatoCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Masaaki MiyakawaCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. tamukou@yokohama-cu.ac.jp.
Akira KanamoriCommittee of Hypertension and Kidney disease, Kanagawa Physicians Association, Yokohama, Japan.
Kanagawa Prefecture Medical Association · JPYokohama City University · JPKitasato University · JPTokai University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 inhibitor (SGLT2-I) shows excellent antihypertensive effects in addition to its hypoglycemic effects. However, whether body mass index (BMI) affects the antihypertensive effect of SGLT2-I remains unknown. We investigated the impact of baseline BMI on the achievement of target blood pressure (BP) with SGLT2-I treatment in Japanese patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). We retrospectively evaluated 447 Japanese patients with T2DM and CKD treated with SGLT2-I for at least 1 year. The primary outcome was achieving the target BP (<130/80 mmHg) after SGLT2-I treatment. Patients were divided into two groups according to a baseline BMI of 29.1 determined by receiver operating characteristic analysis and analyzed in a cohort model with propensity score matching. In each group, 130 patients were compared by propensity score matching. The target BP achievement rate was significantly higher in the BMI < 29.1 group than in the BMI ≥ 29.1 group (34% and 21%, respectively, p = 0.03). The odds ratio for achieving the target BP in the BMI ≥ 29.1 group was 0.50 (95% confidence interval, 0.28-0.90, p = 0.02). The BMI < 29.1 group had significantly lower systolic and diastolic BPs after SGLT2-I treatment than the BMI ≥ 29.1 group. Only the BMI < 29.1 group was showed a significant decrease in the logarithmic albumin-to-creatinine ratio from baseline after SGLT2-I treatment. In patients with T2DM and CKD, baseline BMI was associated with the antihypertensive effects of SGLT2-I. Patients in the lower baseline BMI group were more likely to achieve the target BP after SGLT2-I treatment. Pretreatment BMI affects the antihypertensice effect of SGLT2 inhibirors in patients with T2DM and CKD.

Indexed as

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAntihypertensive AgentsBlood PressureBody Mass IndexGlucoseHumansHypoglycemic AgentsRetrospective StudiesSodiumSodium-Glucose Transporter 2Antihypertensive AgentsGlucoseHypoglycemic AgentsSodiumSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsBlood pressureBody mass indexChronic kidney diseaseSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID37848562
OpenAlexW4387704829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.